Daxxify
DAXXIFY® is FDA-approved to smooth moderate to severe lines between the brows. It is the only long-lasting frown line treatment powered by a peptide with results that last on average 6 months and up to 9 months for some.
Several factors contribute to the formation of facial lines. Decreased collagen production, cellular changes, genetics, environmental damage, and sun damage may all play a role. Facial lines are also formed by repeated muscle contractions such as frowning, squinting, or raising the eyebrows. These facial expressions cause the skin to furrow and fold, which eventually leads to the formation of wrinkles. DAXXIFY® works below the skin’s surface to temporarily reduce the underlying muscle activity responsible for moderate to severe frown lines.
How is DAXXIFY® different from facial fillers, known as dermal fillers?
DAXXIFY® minimizes the appearance of moderate to severe frown lines by temporarily relaxing the underlying muscles that cause these wrinkles. DAXXIFY® is a long-lasting botulinum type A treatment with a novel peptide.
Facial fillers, also known as dermal fillers, are typically made of hyaluronic acid and are used to add volume, fullness, and structure to areas of the face. They can help contour cheekbones, soften lines around the nose and mouth, and volumize lips. Dermal fillers target volume loss rather than muscle-related wrinkles.
Before and after
Schedule Your DAXXIFY Consultation Today
If you’re ready to relax your facial wrinkles with DAXXIFY, call to schedule your consultation or treatment session today.
*At least 50% of patients in clinical studies had no or minor frown lines 6 months after treatment. Between 3% and 5% of patients in clinical studies had no or minor frown lines 9 months after treatment. In other safety studies, between 5% and 17% of patients still had noticeable improvement 9 months later.
Daxxify available at the following locations
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.